OPPORTUNITY™: A large-scale randomized clinical trial of growth hormone in hemodialysis patients

Nephrology Dialysis Transplantation

Volumn 26, Issue 12, 2011, Pages 4095-4103

  Kopple, Joel D ^a,b,c   Cheung, Alfred K ^d,e   Christiansen, Jens Sandahl ^f   Djurhuus, Christian Born ^g   El Nahas, Meguid ^h   Feldt Rasmussen, Bo ⁱ   Mitch, William E ^j   Wanner, Christoph ^k   Göthberg, Marie ^g   Ikizler, Talat Alp ^l  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g NOVO NORDISK A S   (Denmark)

^h Sheffield Kidney Institute   (United Kingdom)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

cardiovascular disease; dialysis; growth factors; lean body mass; mortality

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RECOMBINANT GROWTH HORMONE; TRANSFERRIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UREA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; APPETITE; ARTICLE; BODY FAT; BRAIN HEMORRHAGE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEMALE; FUNCTIONAL STATUS; GLUCOSE BLOOD LEVEL; HAND GRIP; HAND STRENGTH; HEALTH STATUS; HEMODIALYSIS PATIENT; HEMOPTYSIS; HOSPITALIZATION; HUMAN; HYPOALBUMINEMIA; LEAN BODY WEIGHT; MAINTENANCE HEMODIALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TRANSFERRIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT PLANNING; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; WALKING;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOALBUMINEMIA; MALE; MIDDLE AGED; RENAL DIALYSIS; YOUNG ADULT;

EID: 82255164263     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr363     Document Type: Article

References (58)

1. U.S.Renal Data System. USRDS 2007 Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007. H207 Reference tables
2. Kalantar-Zadeh K, Block G, McAllister CJ et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80: 299-307 (Pubitemid 41080002)
3. Kalantar-Zadeh K, Kopple JD, Block G et al. A malnutritioninflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38: 1251-1263 (Pubitemid 34193111)
4. Cano NJ, Fouque D, Roth H et al. Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: a 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 2007; 18: 2583-2591 (Pubitemid 47378875)
5. Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 37: S66-S70 (Pubitemid 32048027)
6. Moller N, Copeland KC, Nair KS. Growth hormone effects on protein metabolism. Endocrinol Metab Clin North Am 2007; 36: 89-100
7. Ericsson F, Filho JC, Lindgren BF. Growth hormone treatment in hemodialysis patients-a randomized, double-blind, placebocontrolled study. Scand J Urol Nephrol 2004; 38: 340-347 (Pubitemid 39277295)
8. Feldt-Rasmussen B, Lange M, Sulowicz W et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18: 2161-2171 (Pubitemid 47041081)
9. Garibotto G, Barreca A, Russo R et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99: 97-105 (Pubitemid 27058299)
10. Hansen TB, Gram J, Jensen PB et al. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol 2000; 53: 99-107 (Pubitemid 30082243)
11. Iglesias P, Diez JJ, Fernandez-Reyes MJ et al. Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis 1998; 32: 454-463 (Pubitemid 28411219)
12. Iglesias P, Diez JJ, Fernandez-Reyes MJ et al. Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. Nephrol Dial Transplant 2002; 17: 260-264 (Pubitemid 34157140)
13. Ikizler TA, Wingard RL, Breyer JA et al. Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int 1994; 46: 1178-1183 (Pubitemid 24319959)
14. Jensen PB, Hansen TB, Frystyk J et al. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone. Clin Nephrol 1999; 52: 103-109 (Pubitemid 29387166)
15. Johannsson G, Bengtsson BA, Ahlmen J. Double-blind, placebocontrolled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis 1999; 33: 709-717 (Pubitemid 29159937)
16. Kopple JD, Brunori G, Leiserowitz M et al. Growth hormone induces anabolism in malnourished maintenance haemodialysis patients. Nephrol Dial Transplant 2005; 20: 952-958 (Pubitemid 40704032)
17. Kotzmann H, Yilmaz N, Lercher P et al. Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int 2001; 60: 1578-1585 (Pubitemid 32960055)
18. Pupim LB, Flakoll PJ, Yu C et al. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr 2005; 82: 1235-1243 (Pubitemid 43779722)
19. Schulman G, Wingard RL, Hutchison RL et al. The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients.AmJKidneyDis 1993; 21: 527-534 (Pubitemid 23160514)
20. Ziegler TR, Lazarus JM, Young LS et al. Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol 1991; 2: 1130-1135
21. Kopple JD, Cheung AK, Christiansen JS et al. OPPORTUNITY: a randomized clinical trial of growth hormone on outcome in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1741-1751
22. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Helsinki Finland: The 18th WMA General Assembly, 1964. http://www. wma.net/en/30publications/10policies/b3/(17 June 2011, date last accessed)
23. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Seoul, Korea: 59thWMAGeneral Assembly, 2008. http://www.wma.net/en/30publications/10policies/b3/(17 June 2011, date last accessed)
24. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice 967. 1996. http://www.ich.org/fileadmin/ Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline. pdf (17 June 2011, date last accessed)
25. Korevaar JC, Merkus MP, Jansen MA et al. Validation of the KDQOL-SF: a dialysis-targeted health measure. Qual Life Res 2002; 11: 437-447 (Pubitemid 34666523)
26. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108 (Pubitemid 127453463)
27. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and metaanalysis. Value Health 2008; 11: 733-741 (Pubitemid 352032818)
28. Manns B, Johnson JA, Taub K et al. Quality of life in patients treated with hemodialysis or peritoneal dialysis: what are the important determinants? Clin Nephrol 2003; 60: 341-351 (Pubitemid 37407692)
29. Davison SN, Jhangri GS, Johnson JA. Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: a simple assessment of symptom burden. Kidney Int 2006; 69: 1621-1625
30. International Conference on Harmonisation. ICH Guideline E9: Statistical Principals for Clinical Trials. 1998. http://www.ich.org/fileadmin/Public-Web- Site/ICH-Products/Guidelines/Efficacy/E9/Step4/E9-Guideline.pdf (17 June 2011, date last accessed)
31. Kober L, Rustom R,Wiedmann J et al. Cardiovascular effects of growth hormone in adult hemodialysis patients: results from a randomized controlled trial. Nephron Clin Pract 2010; 115: c213-c226
32. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808 (Pubitemid 36315558)
33. Kalantar-Zadeh K, Block G, Humphreys MH et al. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 2004; 15: 442-453 (Pubitemid 38140786)
34. Suliman ME, Qureshi AR, Barany P et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727-1735 (Pubitemid 30207932)
35. Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-614 (Pubitemid 34102603)
36. Beauregard C, Utz AL, Schaub AE et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93: 2063-2071 (Pubitemid 351831516)
37. Franco C, Andersson B, Lonn L et al. Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007; 92: 2644-2647 (Pubitemid 47037370)
38. Colao A, Baldelli R, Marzullo P et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 2000; 85: 193-199 (Pubitemid 32268813)
39. Colao A, Ferone D, Marzullo P et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-152 (Pubitemid 38269977)
40. Kahaly G, Olshausen KV, Mohr-Kahaly S et al. Arrhythmia profile in acromegaly. Eur Heart J 1992; 13: 51-56
41. Rodrigues EA, Caruana MP, Lahiri A et al. Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. Br Heart J 1989; 62: 185-194 (Pubitemid 19217073)
42. Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications. Clin Endocrinol (Oxf) 2008; 69: 347-358
43. Juul A, Scheike T, DavidsenMet al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106: 939-944 (Pubitemid 34925327)
44. Colao A, Spiezia S, Di SC et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005; 28: 440-448 (Pubitemid 43162741)
45. Colao A, Di SC, Savanelli MC et al. Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res 2006; 16 (Suppl A): S41-S48
46. Amato G, Carella C, Fazio S et al. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993; 77: 1671-1676 (Pubitemid 24000933)
47. Rabkin R, Awwad I, Chen Y et al. Low-dose growth hormone is cardioprotective in uremia. J Am Soc Nephrol 2008; 19: 1774-1783
48. Fouque D, Peng SC, Kopple JD. Impaired metabolic response to recombinant insulin-like growth factor-1 in dialysis patients. Kidney Int 1995; 47: 876-883
49. Ding H, Gao XL, Hirschberg R et al. Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest 1996; 97: 1064-1075 (Pubitemid 26074153)
50. Zheng Z, Sun DF, Tummala P et al. Cardiac resistance to growth hormone in uremia. Kidney Int 2005; 67: 858-866 (Pubitemid 41623310)
51. Jensen PB, Ekelund B, Nielsen FT et al. Changes in cardiac muscle mass and function in hemodialysis patients during growth hormone treatment. Clin Nephrol 2000; 53: 25-32 (Pubitemid 30046900)
52. Powell DR, Liu F, Baker BK et al. Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group. Kidney Int 1997; 51: 1970-1979 (Pubitemid 27252770)
53. Voerman HJ, Van Schijndel RJ, Groeneveld AB et al. Effects of recombinant human growth hormone in patients with severe sepsis. Ann Surg 1992; 216: 648-655
54. Voerman BJ, Strack Van Schijndel RJ, Groeneveld AB et al. Effects of human growth hormone in critically ill nonseptic patients: results from a prospective, randomized, placebo-controlled trial. Crit Care Med 1995; 23: 665-673
55. Takala J, Ruokonen E, Webster NR et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785-792 (Pubitemid 29420473)
56. Vincent JL. Metabolic support in sepsis and multiple organ failure: more questions than answers. Crit Care Med 2007; 35: S436-S440
57. Kavanagh BP, McCowen KC. Clinical practice. Glycemic control in the ICU. N Engl J Med 2010; 363: 2540-2546
58. Meyfroidt G, Ingels C, Van den BG. Glycemic control in the ICU. N Engl J Med 2011; 364: 1280